Currently, a small molecule targeting MCT1, AZD3965, is in a Phase I clinical trial as an anti-cancer therapeutic [21,22], indicating MCT1 as a valuable biomarker for breast cancer. The gene discussed is SLC16A1; the disease is cancer.